Use the power of over 35 years of data to discover global trends impacting today’s drug development industry.
How it helps
Easily identify opportunities or market saturation with Pharmaprojects. Our expert analysts track new molecular targets entering pipelines, in-and-out licensing activity and conduct primary research on your behalf to uncover additional information around your chosen drug or company. Pharmaprojects links to Trialtrove’s clinical trial intelligence, leveraging the power of both to ensure you stay on top of every clinical trial development for your disease, company, or therapeutic mechanism of interest.
How it works
Pharmaprojects’ intuitive interface supports fast access to drug development results for specific diseases, companies, and countries. These results can appear as graphics-driven analytic dashboards or exportable files.
Quickly tap into Pharmaprojects’ comprehensive data to support your next R&D decision.
Gain vital insight into study feasibility, site selection, and investigator prioritization with granular data from the new Informa Pharma Intelligence Patient Proximity API. Protect yourself against costly trial delays by using it to choose the right investigators with relevant and sizable patient proximity.
Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet...
Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.
Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends
Don’t miss your view into the NAS that made an impact last year, your follow-up to the Pharma R&D Annual Review 2020 webinar.
Recently, Pharma Intelligence brought you the Pharma R&D Annual Review 2020 Webinar, followed up with the NAS (New Active Substances) Infographic. We now invite you to go even deeper into pharma R&D successes for 2019 with your free copy of the NAS Supplement.
The pharma industry is moving into a new decade, and Pharmaprojects is here with insights into what we can expect in the year ahead. Join us to examine the trends and pipelines in a new level of granular detail. Get a taste of the direction R&D is heading in the Pharma R&D Annual Review Webinar.
To mark Pharmaprojects’ 40th year as the leading drug intelligence service, celebrate with us as we revisit key events and milestones for Pharmaprojects and the biopharma industry as a whole.
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.
Using new, granular data from Pharmaprojects, part of the Citeline suite of tools, this infographic will explore: The 2020 Pipeline by Phase Top Companies Mechanisms and Targets Types of Pipeline Drugs
For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
Citeline, Sitetrove, Trialtrove, Pharmaprojects
Citeline is the industry’s most comprehensive, reliable and up-to-date global clinical trial intelligence suite, designed to help you save time and money by enrolling patients faster. Our team of more than 250 industry experts transform data into knowledge, integrating robust drug, trial, investigator, and site intelligence.
Take the analysis from the Informa Pharma Intelligence R&D Annual Review 2019 further with the Pharma R&D Annual Review 2019 Supplement: New Active Substances Launched During 2018. This essential whitepaper uses critical data from Pharmaprojects to examine the new entities that were successfully launched to market last year.
Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.
Pharma R&D Annual Review 2019 is based on the stats and data from from Pharmaprojects, part of Informa’s Citeline family of intelligence solutions. Authored for the 27th time by Ian Lloyd, Senior Director, Pharmaprojects.
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: